AASraw inogadzira NMN neNRC powders muhuwandu!

Afatinib

Rating: Category:

Afatinib powder, inotengeswa pasi pezita rekuti Gilotrif pakati pevamwe, mushonga unoshandiswa kurapa isiri-diki cell lung carcinoma (NSCLC) .Iyo ndeya tyrosine kinase inhibitor mhuri yemishonga.Inotorwa nemuromo.

Product Description

Basic Hunhu

Product Name Afatinib Upfu
CAS Number 439081-18-2
Molecular Formula C24H25ClFN5O3
Formula Weight 485.9
Synonyms Afatinib Upfu;

439081-18-2;

850140-72-6;

BIBW2992;

Tovok.

Kuonekwa White crystalline powder
Kuchengeta uye Kubata Zvichengetedze pamhepo tembiricha uye kure nekupisa kwakanyanya uye hunyoro.

 

Afatinib Powder Tsananguro

Afatinib powder, inotengeswa pasi pezita rekuti Gilotrif pakati pevamwe, mushonga unoshandiswa kurapa isiri-diki cell lung carcinoma (NSCLC) .Iyo ndeya tyrosine kinase inhibitor mhuri yemishonga.Inotorwa nemuromo.

Afatinib powder inonyanya kushandiswa kurapa kesi dzeNSCLC dzinochengeta shanduko muepidermal kukura factor receptor (EGFR) gene.

 

Afatinib Powder Maitiro Ekuita

Kunge lapatinib uye neratinib, afatinib poda ipuroteni kinase inhibitor iyo zvakare isingadzoreke inodzivirira epidermal kukura chinhu receptor 2 (Her2) uye epidermal yekukura factor receptor (EGFR) kinases. Afatinib powder haingoshandisi chete pakurwisa shanduko yeEGFR yakanangwa nechizvarwa chekutanga tyrosine-kinase inhibitors (TKIs) senge erlotinib kana gefitinib, asiwo nekushanduka kushoma kunoenderana nemishonga iyi. Nekudaro, haishande pakurwisa T790M mutation iyo inowanzoda chizvarwa chechitatu zvinodhaka senge osimertinib Nekuda kwebasa rayo rekuwedzera kurwisa Her2, iri kuongororwa nekenza yemazamu pamwe neekanzara inotungamirwa neEGGR neHer2.

 

Afatinib Powder Kunyorera

Afatinib powder yakagamuchira mvumo yekutonga kuti ishandiswe sekurapa kweiyo isiri-diki kenza yemapapu kenza, kunyange paine humbowo huri kubuda hwekutsigira kushandiswa kwayo mune mamwe kanzira senge kenza yemazamu.

 

Afatinib Powder Side Mhedzisiro & Yambiro

Zvakajairika (> 10% frequency)

▪ Manyoka (> 90%)

▪ Rash / dermatitis acneform

▪ Stomatitis

▪ Paronychia

▪ Kuderedza kudya

▪ Mhuno yakabuda ropa

▪ Kunonoka

▪ Ganda rakaoma

 

Zvakajairika (1-10% frequency)

▪ Kushaya mvura mumuviri, Ravidza shanduko, Ziso rakaoma

▪ Cystitis, Cheilitis, Fivha

▪ Kumhanya / kumhanyisa mhino

▪ Kuderera kwe potassium muropa

▪ Kubatana

▪ ALT yakawedzerwa

▪ Yakawedzera AST

▪ Hand-foot syndrome

▪ Tsandanyama tsandanyama

▪ Kukanganiswa neitsvo uye / kana kukundikana

 

Hazvina kujairika (0.1-1% frequency)

▪ Keratitis

▪ Hosha yemapapu yepakati

 

Reference

[1] "Gilotrif (afatinib powder) piritsi, firimu yakavharwa". Zuva Nezuva. Boehringer Ingelheim Pharmaceuticals, Inc. 18 Gumiguru 2019. Yakadzorerwa 4 Mbudzi 2020.

[2] Spreitzer H (13 Chivabvu 2008). "Neue Wirkstoffe - Tovok". Österreichische Apothekerzeitung (muchiGerman) (10/2008): 498

[3] Minkovsky N, Berezov A (Zvita 2008). "BIBW-2992, inonzi receptor receptor tyrosine kinase inhibitor yekurapa mamota akasimba". Pfungwa Dzazvino Mukutsvagisa Zvinodhaka. 9 (12): 1336-46. PMID 19037840.

[4] "Afatinib Upfu". US Kudya neDrug Administration. 12 Chikunguru 2013. [dead link] [5] "Giotrif Afatinib Powder (as afatinib dimaleate)" (PDF). TGA eBusiness Services. Mari yezvikamu Boehringer Ingelheim Pty Limited 7 Mbudzi 2013. Yakadzorerwa 28 Ndira 2014.

[6] Vavalà T (2017). "Basa reafatinib powder mukurapa kwepamberi yemapapu squamous cell carcinoma". Clinical Pharmacology. 9: 147-157. doi: 10.2147 / CPAA.S112715. PMC 5709991. PMID 29225480.